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The authors have studied oncostatin M secretory activity of cells of two lines of
transplantable melanoma with different biological properties. The level of OSM
in melanoma cells supernatant was determined by ELISA test and OSM bioactivi-
ty was measured by using biotest line sensitive to OSM cytostatic activity
 A 375 melanoma cells. OSM presence was confirmed in cellular lysates by
western blot. It has been demonstrated that a spontaneous alteration of the
transplantable melanotic melanoma line into an amelanotic line connected with
tumour progression was accompanied by an increase of OSM release.
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INTRODUCTION
According to recent reports, Oncostatin M (OSM) is
a glycoprotein cytokine playing, among a multitude
of biological functions, a role in the inhibition of
melanoma cell growth, and the effect of the inhibi-
tion seems to depend on the melanoma cell pheno-
type [3,6,8,9,20].
Simultaneously, many authors have indicated that
the sensitivity of human melanoma cells to OSM ac-
tivity depends on the rate of growth and degree of
melanoma progression. The same melanoma cells are
able to synthesise and secrete OSM [9,13,16,18,23].
According to contemporary views the secretion
by tumour cells of autocrine factors regulating their
growth and interactions between the tumour and
the host is a very interesting problem in tumour bio-
logy, but still far from resolution.
Therefore, in this work (a continuation of our
study on the immunobiology of two transplantable
melanoma lines of common origin but differing in
many biological features) we attempted to find out
if there exist any differences in OSM secretion by the
native melanoma cells and the amelanotic melano-
ma line cells which originated from the melanotic
form by a spontaneous alteration in which the loss
of pigment was accompanied by an acceleration of
growth, a lower degree of differentiation and high-
er immunogenicity [1,11].
MATERIAL AND METHODS
Animals
3-4-month-old male Syrian (golden) hamsters
Mesocricetus auratus Waterhouse, were purchased
from the Central Animal Facilities of the Silesian
Medical University, Katowice, Poland. The animals
were then conventionally reared at the Departments
animal facility and fed standard diet and tap water
ad libitum. The experimental procedures were ap-
proved by the Animal Ethics Committee at the Med-
ical University of Gdaæsk and conformed to the Na-
tional Health and Medical Research Councils guide
for the care and use of laboratory animals.
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Transplantable melanomas
The tumours were transplantable melanotic and
amelanotic melanomas.
The melanotic melanoma line derived from a spo-
ntaneous melanoma of the skin, which had appeared
spontaneously in a breed of golden hamsters in 1959
and was described by Bomirski [1] in 1977 as Ma
line.
The amelanotic melanoma line originated from
the melanotic form by a spontaneous alteration de-
scribed in 1977 as Ab line [1].
These melanoma lines differ in many biological
features.
Isolation of melanotic and amelanotic melano-
ma cells
Melanoma cells were isolated from solid tumours by
a non-enzymatic method, described previously, to
obtain single-cell suspensions [2]. The suspension
consisted 9598% of viable cells (estimated by test
with trypan blue).
Preparation of supernatants of melanoma cells
culture
Isolated melanoma cells at the concentration 5 ¥ 10 5/ml
were incubated in RPMI 1640 (culture medium)
(Biomed Lublin) with 10% FCS (foetal calf serum;
GIBCO) and antibiotics (100 U/ml penicillin, 100 mg/ml
streptomycin) for 1, 6, 24, 48 h in 6-well plates
(Corning) in 5% CO2 at 37°C. After that time super-
natants were harvested and stored at 70oC until
later use.
A 375 cells (human malignant melanoma, kindly
provided by Prof. J. Georgiades, Amarillo Cell Cul-
ture, USA) were used as control of other melanoma
cells; 5 ¥ 10 5/ml A 375 cells were incubated in DMEM
(Dulbeccos Modified Eagle Medium) (Biomed Lub-
lin) with 10% FCS (foetal calf serum; GIBCO) and
antibiotics (100 U/ml penicillin, 100 mg/ml strepto-
mycin) for 6 and 24 h in 6-well plates (Corning) in
5% CO2 at 37°C. After that time supernatants were
harvested and stored at 70oC until later use.
Cytokines determination by biological assay and
ELISA test
OSM bioactivity in melanoma cells supernatants was de-
termined for its ability to inhibit proliferation of A 375
melanoma cells (biotest line sensitive to OSM cytostat-
ic activity) by a modification of the procedure described
by Linsley et al. [14] in 96-well plate (Corning) using
a MTT dye-binding assay (3-[4,5-dimethylthiazol-2-yl]
-2,5-diphenyltetrazolium bromide; 5 mg/ml PBS; SIG-
MA). Control sample were A 375 cells (1 x 105/ml)
incubated in medium without supernatants. Ab-
sorbance at 570 nm was determined on a micro-
plate reader (BioRad). Samples were assayed in trip-
licate.
Units of OSM biological activity were defined as
the volume of supernatant required to cause a 50%
inhibition of the growth of A 375 melanoma cells.
Recombinant mouse OSM (R & D, Minneapolis
MN, USA) was used as standard with a specific ac-
tivity 29 ng/ml.
Level of OSM in melanoma cells supernatants was
determined by the Quantikine human OSM immu-
noassays (Research and Diagnostic Systems, Minne-
apolis, MN, USA), which is a solid-phase ELISA. The
assay was performed as described in the instructions.
Absorbance at 450 nm was determined on a micro-
plate reader (BioRad). The concentration of cytoki-
nes in the supernatants was determined by compa-
ring the optical density of the samples to the stan-
dard curve (2-1500 pg/ml OSM). Sensitivity limits of
the ELISA for OSM was 2.1 pg/ml. Samples were as-
sayed in triplicate.
Western blot detection of OSM
Fresh isolated melanoma cells (2 x 106) were lysated
in hypotonic Tris/Nonidet 40/Tween-100 buffer with
protease inhibitor cocktail (aprotinin 100 mg/ml, le-
upeptin mg/ml, iodoacetamide 1.8 mg/ml, phenyl-
methyl sulphonyl fluoride (PMSF) at 1 mM) for 1 hour
on ice, spun for 5 minutes at 10,000 rpm, superna-
tants were collected and stored at 70°C until fur-
ther processing. Proteins contained in the lysates
were resolved by standard polyacrylamide gel elec-
trophoresis (SDS-PAGE) on a 12% gel [12]. Separat-
ed proteins were then electrophoretically trans-
ferred onto nitrocellulose (60 V, 2.5 h). Nitrocellu-
lose sheets (Schleicher & Schuel) with transferred
protein were then processed for OSM detection, i.e.
blocked with 3% BSA (bovine serum albumine) in
PBS, washed and exposed to the biotinylated anti-
mouse OSM (R & D, Minneapolis MN, USA) for 2 h
at room temperature. After washing out the un-
bound antibody, antibody that was bound to the
membrane was colorimetrically detected using avi-
din-alkaline phosphatase solution (BioRad) and BCIP
(5-bromo-4-chloro-3-indolylphosphate p-toluidine
salt)/NBT (p-nitro blue tetrazolium chloride; BioRad)
solution.
Recombinant mouse OSM (R & D, Minneapolis MN,
USA) was applied as standard protein. Prestained SDS-
PAGE Standards (BioRad ) was used as molecular
weight marker.
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Protein estimation
Total protein content in 1, 6, 24, 48 h cultured me-
lanoma cells supernatants was determined by the
method of Lowry et al. [15], using bovine albumin
fraction V (Sigma) as standard. In all experiments
protein content in wells containing medium with-
out melanoma cells was also measured and subtract-
ed from experimental values. Samples were assayed
in triplicate.
Statistical evaluation
Group data expressed as mean – S.D. were statisti-
cally estimated by nonparametric U Mann-Whitneys
test by STATISTICA programme. The p value of less
than 0.05 was considered to represent a statistically
significant difference.
RESULTS
The content and biological activity of OSM
The results obtained are presented in Figure 1. They
showed that both transplantable melanoma line cells
were able to secrete OSM already after 1h incuba-
tion. Quantitative estimations by ELISA test indicat-
ed that melanotic melanoma cells secreted 5.2 pg/ml
and amelanotic melanoma  cells 5.7 pg/ml after that
time.
During 24 h incubation there were no marked
differences in OSM secretion by those two melano-
ma cells. After that time both melanoma cells se-
creted only about 10% more OSM in comparison with
the OSM level after 1h.
After another 24 h the OSM content in the su-
pernatants decreased by about 28% in the melano-
tic melanoma cells (in comparison with highest value
after 6 h) and by about 18% in the amelanotic me-
lanoma cells.
The biological activity of OSM, presented in
Figure 1, showed that during 48 h this activity
changed, but the observed changes were not corre-
lated with the above-mentioned OSM content esti-
mated by ELISA test.
After 1 h incubation the content of OSM in the
supernatants of both melanoma cells was over 5 pg/ml
while the biological activity of this cytokine was at
the detectability level. Only after 6 h did we observe
an increase in the biological activity of OSM: 6-fold
in melanoma and 5-fold in amelanotic melanoma
cells, while the content of OSM did not change.
The biological activity of OSM showed a tenden-
cy to increase during a further incubation time up to
48 h even when its content in the supernatants de-
creased. When comparing the ability of both mela-
noma lines to secrete OSM it should be borne in mind
that the amelanotic melanoma line cells were more
active in OSM secretion, and the OSM biological ac-
tivity was also higher than in the melanotic melano-
ma cells.
Changes observed during 48 h were more stable
in the amelanotic melanoma cells.
Both transplantable melanoma cells secreted less
OSM than A 375 cells (after 6 h 7.0 – 2.5 pg/ml, 24 h
8.4 – 1.7 pg/ml) used as control of OSM secretion
by other than transplantable melanoma cells.
OSM presence was confirmed in cellular lysates
by western blot (Fig. 2).
Total proteins content and calculation of OSM
content per 1 mg of the protein secreted
The results obtained regarding the quantitative esti-
mations of the dynamic secretion of total proteins
by both transplantable melanoma cells are present-
ed in Figure 3.
The results showed that the profile of dynamic
secretion of protein was different from OSM secre-
tion.
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Figure 1. OSM secretion by transplantable melanoma cells esti-
mated by ELISA test and by biological activity test. The values
are the means – SD of 412 experiments. Experiments done in
triplicate. P values were calculated using U Mann-Whitney test.
*  statistically significant (p < 0.01) increase of Ab melanoma
cells OSM activity after 24, 48 h in comparison with 1 h culture;
**  statistically significant (0.001 < p < 0.05) increase of Ma
melanoma cells OSM activity after 6, 24, 48 h culture in compari-
son with 1 h culture
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The secretory activity of both transplantable mela-
noma cells was higher during 6 h incubation; later
on we observed a decrease in protein secretion: by
about 64% in the melanotic melanoma cells and by
over 58% in the amelanotic melanoma cells.
This decreasing tendency stayed during the next
24 h observation. Moreover, it was noticed that cells
of the native melanoma line secreted proteins more
actively than the amelanotic melanoma cells, during
the whole incubation time; for 1 h and 6 h incuba-
tions these differences were statistically significant.
In that situation the calculation of the OSM con-
tent in 1 mg of total protein secreted showed that
after 24 h there was 34.5% more OSM in the super-
natant of  amelanotic melanoma cells than in the
supernatant of native line cells, and after 48 h this
value increased to 52%. It is worth noticing that af-
ter that time the protein secretion decreased in both
melanoma cells to a similar degree, by about 17%.
DISCUSSION
Our comparative study regarding the secretion of
OSM by cells of two lines of transplantable melano-
mas showed that a spontaneous alteration of a na-
tive melanotic line into an amelanotic line with
a more aggressive tumorigenic phenotype is accom-
panied by an increase in vitro of the OSM secretory
activity; this alteration is also connected with the
progression of this melanoma but it does not con-
cern the conspicuous changes in the dynamics of
OSM secretion or in its biological activity.
In the results obtained it is worth noticing that
the OSM secreted during a 6-hour culture does not
show any biological activity, and that OSM activity
in the supernatants was highest after a 48-hour cul-
ture, while the content of cytokine in the superna-
tant decreased.
What is interesting is the fact that the amelanotic
line of melanoma tumour with a higher rate of
growth secreted more OSM (the decrease of OSM
secretion after 48 hours of culture is smaller than in
the line growing more slowly) than the native mela-
notic line characterised by a slower rate of growth.
Thus, these results seem to suggest that the OSM
secreted by the cells of the amelanotic melanoma
line does not affect these cells as an autocrine factor
inhibiting the growth of melanoma. It is necessary
to take into account also Montero et al. [19] who
report that OSM increased the releasing of soluble
sgp 130 by melanoma cell lines. This tumour-derived
sgp 130 binding OSM in supernatants inhibits the
growth-inhibiting activity of cytokine.
Our results may also suggest that the spontaneous
alteration of a melanotic melanoma line into an amela-
notic form accompanied by tumour progression is con-
nected with a diminished susceptibility of this line of
melanoma to the antiproliferative action of OSM.
This finding is consistent with the concept of ac-
quired multicytokine resistance during melanoma
progression, underlined by some authors [9,16,23].
Figure 3. Dynamics of proteins and OSM (in 1 mg secreted proteins)
secretion by transplantable melanoma cells. The values are the means
– SD of 612 experiments. Experiments done in triplicate. P values
were calculated using U Mann-Whitney test.
*  statistically significant (p < 0.05) decrease of protein se-
cretion by Ab melanoma cells in comparison with Ma melanoma
cells after 1, 6 h culture;
**  statistically significant (p < 0.001) decrease of protein
secretion by Ma melanoma cells after 24, 48 h culture in
comparison with 1, 6 h culture;
***  statistically significant (p < 0.001) decrease of protein
secretion by Ab melanoma cells after 24, 48h culture in compari-
son with 1, 6 h culture
1
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Figure 2. Western blot detection of oncostatin M (28 kDa) in cel-
lular lysates of transplantable melanoma tumors. Lane 1 is for
positve control of recombinant mouse OSM; lane 2 for negative
control of culture medium without cells; lanes 3 and 4 for lysates
of melanotic and amelanotic melanoma cells, respectively. Re-
sults from one of three separate experiments with similar results
are presented.
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On the other hand, this observation agrees with
Gibbs et al. [5] showing a lack of regularity of different
melanoma lines in the reactivity to the antiprolifera-
tive action of OSM.
However, considering the reports that OSM is
a multifunctional cytokine, it is difficult in the case
of transplantable melanoma to connect the secre-
tion of OSM only with the function of an autocrine
factor regulating melanoma growth.
Studies by Giavazzi [4] and Heyman et al. [7] dem-
onstrated the ability of OSM to modulate the ex-
pression of adhesion molecules on the melanoma
cell surface, suggesting a potential role of this cy-
tokine in the modulation of tumour progression.
Investigations indicating OSMs ability to modify
the activity of tissue inhibitor of metaloproteinase
explain the changed conditions in the connective tis-
sue surrounding the tumour, and the potential role
of this cytokine in neoplastic metastases [17,22].
It is possible to assume that the OSM secreted by
melanoma cells changes the local environment in
another way, by influencing the cells involved in the
immune response and modifying their function.
Some authors think that OSM is important in the
melanoma progression, inducing tumour cells to re-
lease other cytokines [18].
Our earlier study showed that the progression of
transplantable melanoma is associated with a de-
creased secretion of IL-6 and TNF-a [24], whereas in
the present work OSM secretion increases; this seems
to indicate that in the biology of transplantable
melanoma OSM plays a different role than the above-
mentioned cytokines.
Perhaps the OSM secreted by melanoma cells in-
fluences the cells of the immunological system, in-
ducing cytotoxicity of the effector cells but only for
a melanoma with a lower immunogenicity, accor-
ding to Revels [21] suggestion, and for this reason
the rate of growth of the melanoma form with
a higher immunogenicity does not decrease.
Our previous findings also suggest that the amela-
notic melanoma line with a higher immunogenicity,
inducing macrophage secretion of different cytoki-
nes, including OSM, was able to suppress macropha-
ges and evoke conditions of tumour escape from
immunosurveillance [10].
Furthermore, the fact that it is in a 48 h culture
that the secretion of total protein by melanoma cells
decreases but OSM secretion and its biological ac-
tivity are highest, also seems to show that in the
biology of transplantable melanoma this cytokine
may perform a special function, not connected di-
rectly with the regulation of the growth rate. This
seems possible particularly when we take into ac-
count the above-mentioned observation showing
that in vitro secretion of such cytokines as TNF-a and
IL-6 in 48-hour cultures decreased [24].
Thus, on the basis of the results obtained, we may
suppose that the elevated levels of OSM secreted by
the cells of a melanoma with a higher immunogenicity
and higher growth rate are to a lesser degree an auto-
crine factor regulating the growth of melanoma, but
may to a greater extent be involved in the immuno-
modulatory function, changing the tumour-host int-
eraction during melanoma progression.
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